PF-Atlas › Clinical Trials › NCT00625469

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

bosentan · Phase 4

Registry ID
NCT00625469
Phase
Phase 4
Status
Withdrawn
Drug / intervention
bosentan
Sponsor
Rajan Saggar
Start
2007-10
Locations
2

About this trial

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no significant data to support the use of pulmonary vasodilators for PAH in the setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH either at rest or during exercise. The study hypothesis is that bosentan may improve morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or exercise PAH.

View NCT00625469 on ClinicalTrials.gov →

Explore related

All bosentan trialsAll IPF trials

Related trials

Bosentan — NCT00318175Bosentan — NCT00070590bosentan — NCT01518595Bosentan — NCT00631475bosentan — NCT00071461Bosentan — NCT00637065
Medical disclaimer. This page summarizes public trial data for NCT00625469 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.